MannKind Corp (MNKD) stock
MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30127% above fair value
$4.07+0.00 (0.00%)
Close on Nov 18, 2026Market cap $1.31BP/E –Yield –
MannKind operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
MannKind's operating income for the twelve months ending Jun 30, 2026 was $9.19M, down 86.2% year over year. For fiscal 2025 it was $38.80M, down 46.5% from the year before. The highest annual figure on record is $72.59M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.80M | -46.5% |
| FY2024 | Dec 31, 2024 | $72.59M | +736.4% |
| FY2023 | Dec 31, 2023 | $8.68M | – |
| FY2022 | Dec 31, 2022 | -$64.11M | – |
| FY2021 | Dec 31, 2021 | -$47.02M | – |
| FY2020 | Dec 31, 2020 | -$47.91M | – |
| FY2019 | Dec 31, 2019 | -$44.60M | – |
| FY2018 | Dec 31, 2018 | -$76.60M | – |
| FY2017 | Dec 31, 2017 | -$108.19M | -260.9% |
| FY2016 | Dec 31, 2016 | $67.26M | – |
| FY2015 | Dec 31, 2015 | -$344.66M | – |
| FY2014 | Dec 31, 2014 | -$179.63M | – |
| FY2013 | Dec 31, 2013 | -$169.40M | – |
| FY2012 | Dec 31, 2012 | -$146.96M | – |
| FY2011 | Dec 31, 2011 | -$140.54M | – |
| FY2010 | Dec 31, 2010 | -$152.50M | – |
| FY2009 | Dec 31, 2009 | -$209.78M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$350.00K | -106.6% |
| Q1 FY2026 | Mar 31, 2026 | -$1.67M | -107.5% |
| Q4 FY2025 | Dec 31, 2025 | -$7.69M | -129.0% |
| Q3 FY2025 | Sep 30, 2025 | $18.90M | +48.1% |
| Q2 FY2025 | Jun 30, 2025 | $5.30M | -68.1% |
| Q1 FY2025 | Mar 31, 2025 | $22.29M | +33.3% |
| Q4 FY2024 | Dec 31, 2024 | $26.50M | +237.2% |
| Q3 FY2024 | Sep 30, 2024 | $12.76M | +150.3% |
| Q2 FY2024 | Jun 30, 2024 | $16.61M | +865.1% |
| Q1 FY2024 | Mar 31, 2024 | $16.72M | – |
| Q4 FY2023 | Dec 31, 2023 | $7.86M | – |
| Q3 FY2023 | Sep 30, 2023 | $5.10M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.72M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.45M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.97M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.59M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.27M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.19M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.75M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.13M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.92M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.12M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.35M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.78M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.95M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.73M | – |
| Q3 FY2018 | Sep 30, 2018 | -$21.54M | – |
| Q2 FY2018 | Jun 30, 2018 | -$20.54M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.79M | – |
| Q4 FY2017 | Dec 31, 2017 | -$28.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$28.18M | -123.8% |
| Q2 FY2017 | Jun 30, 2017 | -$31.57M | – |
| Q1 FY2017 | Mar 31, 2017 | -$19.60M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.83M | – |
| Q3 FY2016 | Sep 30, 2016 | $118.23M | – |
See a number that looks wrong?